- News Releases
For patients diagnosed with myelofibrosis, a bone marrow disorder that disrupts the body’s normal production of blood cells, new hope may be on the horizon.
A study, published in the March 1 edition of the New England Journal of Medicine, found the drug Ruxolitinib was able to effectively improve the quality of life for those with intermediate and advanced forms of this chronic condition and reduce symptoms better than existing therapies.
“These were the largest, randomized clinical trials ever performed for Myelofibrosis and represent a significant benefit over therapies we have used in the past,” said Ruben Mesa, M.D., Chair of the Division of Hematology and Medical Oncology at Mayo Clinic in Arizona and an author of the New England Journal of Medicine paper.
In addition to Dr. Mesa, other principal researchers included lead investigator Srdan Verstovsek, M.D. of the MD Anderson Cancer Center in Texas and Claire Harrison, DM, FRCP of St. Thomas’ Hospital in London, U.K.
Three soundbites from Dr. Mesa, one of the study authors, are available in the downloads above.
Title: Dr. Ruben Mesa, Mayo Clinic Hematology/Oncology